Abbott Park, Illinois Wednesday, November 20, 2024, 13:00 Hrs [IST] ...

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

(JAMA Cardiology) Five-year results from the Amulet IDE trial suggested similar performance of the Amulet and Watchman 2.5 ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it’s a celebration.

Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

Cardiologist Dr. Josiah Brown, specializing in minimally invasive therapies, is the newest team member at Alaska Heart & ...